PriceTargets.com logo

Prothena - PRTA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $61.86
  • Forecasted Upside: 266.89%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$16.86 As of 10/4/2024 01:00 AM ET
▲ +0.06 (0.36%)

This chart shows the closing price for PRTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prothena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

Analyst Price Target is $61.86
▲ +266.89% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $61.86, with a high forecast of $87.00 and a low forecast of $24.00. The average price target represents a 266.89% upside from the last price of $16.86.

This chart shows the closing price for PRTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in Prothena. This rating has held steady since January 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$84.00 ➝ $84.00
10/1/2024Bank of AmericaLower TargetNeutral ➝ Neutral$33.00 ➝ $31.00
9/30/2024Cantor FitzgeraldReiterated RatingOverweight
8/14/2024OppenheimerLower TargetOutperform ➝ Outperform$66.00 ➝ $62.00
8/12/2024Cantor FitzgeraldReiterated RatingOverweight
8/9/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$28.00 ➝ $24.00
6/26/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$28.00 ➝ $28.00
5/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$85.00 ➝ $83.00
5/9/2024HC WainwrightLower TargetBuy ➝ Buy$90.00 ➝ $84.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
2/20/2024OppenheimerLower TargetOutperform ➝ Outperform$98.00 ➝ $80.00
2/16/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$81.00 ➝ $85.00
2/16/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$36.00 ➝ $35.00
1/30/2024Bank of AmericaReiterated RatingBuy ➝ Neutral$68.00 ➝ $38.00
1/25/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$43.00 ➝ $36.00
1/9/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$129.00 ➝ $87.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$129.00
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$62.00
11/3/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$83.00 ➝ $81.00
10/23/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$129.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$129.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/4/2023JMP SecuritiesBoost TargetOutperform ➝ Outperform$82.00 ➝ $83.00
7/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$129.00
7/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
5/8/2023Cantor FitzgeraldBoost Target$98.00 ➝ $120.00
5/5/2023HC WainwrightBoost Target$75.00 ➝ $90.00
4/24/2023Leerink PartnersReiterated RatingOutperform
4/24/2023SVB SecuritiesInitiated CoverageOutperform$80.00
4/3/2023HC WainwrightReiterated RatingBuy$75.00
2/27/2023CitigroupLower TargetBuy$76.00 ➝ $72.00
2/24/2023HC WainwrightReiterated RatingBuy$75.00
1/27/2023Piper SandlerInitiated CoverageOverweight$94.00
12/21/2022Cantor FitzgeraldBoost TargetOverweight$91.00 ➝ $98.00
11/15/2022OppenheimerBoost Target$110.00 ➝ $120.00
11/4/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$52.00 ➝ $55.00
10/24/2022CitigroupBoost TargetBuy$65.00 ➝ $71.00
9/29/2022OppenheimerBoost TargetOutperform$100.00 ➝ $110.00
9/28/2022Royal Bank of CanadaBoost Target$45.00 ➝ $52.00
9/28/2022Bank of AmericaUpgradeNeutral ➝ Buy$45.00 ➝ $65.00
9/28/2022JMP SecuritiesBoost Target$50.00 ➝ $81.00
5/25/2022JMP SecuritiesLower TargetMarket Outperform$77.00 ➝ $50.00
2/18/2022CitigroupLower Target$87.00 ➝ $73.00
11/19/2021JMP SecuritiesInitiated CoverageOutperform$77.00
9/30/2021Royal Bank of CanadaBoost TargetOutperform$59.00 ➝ $82.00
9/27/2021OppenheimerBoost TargetOutperform$90.00 ➝ $100.00
9/20/2021Fox-Davies CapitalInitiated CoverageOverweight$14.00
9/17/2021Cantor FitzgeraldBoost TargetOverweight$70.00 ➝ $103.00
9/14/2021OppenheimerBoost TargetOutperform$82.00 ➝ $90.00
8/9/2021OppenheimerBoost TargetOutperform$76.00 ➝ $82.00
7/19/2021Royal Bank of CanadaBoost TargetOutperform$50.00 ➝ $59.00
7/15/2021Cantor FitzgeraldBoost TargetOverweight$63.00 ➝ $70.00
7/13/2021OppenheimerBoost TargetSell ➝ Outperform$54.00 ➝ $76.00
7/13/2021HC WainwrightBoost TargetBuy$58.00 ➝ $75.00
7/13/2021CitigroupBoost TargetBuy$57.00 ➝ $72.00
6/25/2021BTIG ResearchBoost TargetBuy$29.00 ➝ $65.00
6/18/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$12.00 ➝ $49.00
6/11/2021Royal Bank of CanadaBoost TargetOutperform$28.00 ➝ $50.00
6/10/2021HC WainwrightBoost TargetBuy$33.00 ➝ $58.00
6/8/2021OppenheimerBoost TargetPositive ➝ Outperform$45.00 ➝ $54.00
6/8/2021Cantor FitzgeraldBoost TargetOverweight$43.00 ➝ $62.00
6/1/2021OppenheimerBoost TargetOutperform$40.00 ➝ $45.00
5/26/2021CitigroupInitiated CoverageBuy
5/12/2021OppenheimerBoost TargetOutperform$35.00 ➝ $40.00
3/15/2021Jefferies Financial GroupBoost TargetBuy$30.00 ➝ $38.00
3/2/2021OppenheimerReiterated RatingBuy$35.00
2/26/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$14.00 ➝ $28.00
2/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $30.00
2/4/2021HC WainwrightBoost TargetBuy$22.00 ➝ $33.00
2/2/2021OppenheimerBoost TargetOutperform$25.00 ➝ $35.00
2/2/2021BTIG ResearchUpgradeNeutral ➝ Buy$29.00
12/10/2020OppenheimerBoost Target$20.00 ➝ $25.00
12/7/2020HC WainwrightInitiated CoverageBuy$22.00
10/21/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$20.00 ➝ $24.00
9/13/2020OppenheimerReiterated RatingBuy$18.00
7/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00
5/13/2020OppenheimerReiterated RatingHold
5/10/2020NomuraReiterated RatingBuy$19.00
4/23/2020OppenheimerReiterated RatingHold
1/1/2020Nomura SecuritiesReiterated RatingBuy$19.00
12/22/2019Evercore ISIReiterated RatingBuy$14.00
11/27/2019Evercore ISIUpgradeIn-Line ➝ Outperform
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$14.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
3/8/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/7/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 6 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
6/6/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/6/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/4/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prothena logo
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $16.86
Low: $16.59
High: $17.54

50 Day Range

MA: $20.91
Low: $16.65
High: $24.43

52 Week Range

Now: $16.86
Low: $15.52
High: $55.89

Volume

726,028 shs

Average Volume

601,351 shs

Market Capitalization

$906.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: Bank of America Co., Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

7 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $61.86, suggesting a possible upside of 268.2%. Cantor Fitzgerald has the highest price target set, predicting PRTA will reach $87.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $24.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PRTA.

What other companies compete with Prothena?

Other companies that are similar to Prothena include Dynavax Technologies, UroGen Pharma, Akebia Therapeutics, Puma Biotechnology and Marinus Pharmaceuticals. Learn More about companies similar to Prothena.

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is (531) 236-2500 and its investor relations email address is [email protected]. The official website for Prothena is www.prothena.com. Learn More about contacing Prothena investor relations.